Abivax S.A. Stock
Abivax S.A. Stock
Heavy losses for Abivax S.A. today as the stock fell by -€3.500 (-3.260%).
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Abivax S.A. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Abivax S.A. in the next few years
Pros
?
M***** P*******
?
B****
?
S********** s********
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Abivax S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Abivax S.A. | -3.260% | - | - | - | - | - | - |
| Nanobiotix | 0.870% | -5.809% | -11.196% | 798.947% | 34.136% | 643.687% | 90.767% |
| Innate Pharma | -4.170% | -4.340% | -10.697% | -33.534% | -27.974% | -63.987% | -70.472% |
| Poxel S.A. | -5.560% | -12.278% | 0.407% | -53.491% | 3.138% | -64.379% | -96.225% |
Comments
DERFY stimmt der Outperform-Einschätzung der institutionellen Analysten zu
DERFY stimmt am 12.07.2016 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 26.97€ zu.News
EQS-News: Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
EQS-News: Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
EQS-News: Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
EQS-News: Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
EQS-News: Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
EQS-News: Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026